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BACKGROUND 
 
Leaf  (IC50 48,5 μg/mL) and 
root axtract (IC50 44,2 
μg/mL) were active as 
anticancer colon (Mutiah 
dkk, 2014) 
Fractions of root extract  ( 
FDCM IC₅₀ = 0.367 µg/ml, 
FEA IC₅₀ = 0.063 µg/mL 
were higher activity  than 
fraction of leaves extract 
(DCM IC₅₀ = 40.57 µg/mL, 
EA =IC₅₀ = 41.79 µg/ml ) 
Combination with 
chemotheraphy of EA 
fraction 
OBJECTIVE 
To obtain the monotheraphy effect 
of etyl acetat fraction Calotropis 
gigantea roots (EACGR) on human 
breast cancer t47d cell lines.  
To obtain the synergism effect of 
etyl acetat fraction Calotropis 
gigantea roots (EACGR) with 5 
fluorouracil on human breast 
cancer t47d cell lines.  
Benefit 
To give scientific information about anticancer 
activity combination from ethyl acetate fraction of 
Calotropis gigantea roots and 5 Fluorouracil 
To give therapeutic choice for anticancer drugs  
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Denah pengelompokan sampel uji, DOXORUBISIN, 
kombinasi, kontrol sel dan kontrol media  
MATERIAL AND METHODS 
 CGLE : 5-FU/DOX 
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100 ½ IC50 EACGR : 25  ½ IC50 CGLE : 12,5 
CONTROL OF 
CELL 
F 50 ¾ IC50 EACGR : 25 ¾ IC50 CGLE : 12,5 
G 25 IC50 EACGR : 25 IC50 CGLE : 12,5 
CONTROL OF 
MEDIA 
H 12,5  IC50 EACGR : 25  IC50 CGLE : 12,5 
RESULT AND DISCUSSION 
Figure 1.The effect of EACGR, 5-FU monotherapy and combination therphy to the 
morphology of T47D cell line. Cell morphology was examined by using inverted 
microcope with magnification 400x 
CONTROL DOXORUBISIN 
28 EACGR + 62.5 5FU 7 EACGR+ 31.5 5FU 















































CI Fraksi Etil Asetat Calotropis gigantea dan 5 FU 














Figure 3. sinergism effect of EACGR with 5-FU on T47D Cell line  
RESULT AND DISCUSSION 
No 
Kombinsai cell viability 







rata-rata     ±      
SD 
1 7 31.5 58.67 ± 2.198 0.39 sinergis 
  14 31.5 63.16 ± 0.788 1.45 antagonis 
  21 31.5 64.77 ± 1.37 3.88 antagonis kuat 
  28 31.5 64.05 ± 4.52 3.83 antagonis kuat 
2 7 62.5 62.62 ± 4.00 0.92 sinergis ringan 
  14 62.5 64.47 ± 4.33 2.51 antagonis 
  21 62.5 67 ± 4.21 9.87 antagonis kuat 
  28 62.5 61.62 ± 2.60 1.76 antagonis 
3 7 125 53.42 ± 0.54 1.79 antagonis 
  14 125 62.57 ± 1.91 1.83 antagonis 
  21 125 60.48 ± 2.02 1.61 antagonis 
  28 125 59.86 ± 1.57 1.68 antagonis 
4 7 250 58.14 ± 3.42 2.51 antagonis 
  14 250 57.48 ± 1.29 2.99 antagonis 
  21 250 61.33 ± 1.19 2.76 antagonis 
  28 250 61.24 ± 0.62 3.01 antagonis 
CONCLUTION 
1. The data analysis showed that combination therapy of 
EACGR and 5 Fluorouracil have been synergistic effect 
at7 µg/ml EACGR and 32.5 µg/ml  5-FU, with 
Combination Index value (CI) ranging from 0.20 to 
0.07. The effect minor synergistic of this combination 
was showed at dose 7 µg/ml EACGR and 62.5 µg/ml  
5-FU, with Combination Index value (CI) ranging from 
0.7 to 0.9. 
2. Combination therapy of 7 µg/ml EACGR and 32.5 
µg/ml  5-FU have been synergistic anticancer effect 
on human breast cancer cell line T47D. 
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